|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,390.00 KRW | +1.61% |
|
+1.39% | -46.54% |
| Mar. 30 | Abpro Bio Co., Ltd. announced that it has received KRW 3.9999998 billion in funding | CI |
| Mar. 15 | Abpro Bio Co., Ltd. announced that it expects to receive KRW 6 billion in funding | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -2 | -4.31 | -4.26 | -2.89 | -5.37 | |||||
Return on Total Capital | -2.16 | -4.51 | -4.46 | -3.1 | -5.81 | |||||
Return On Equity % | -7.06 | -5.86 | -19.61 | -13.57 | -60.38 | |||||
Return on Common Equity | -6.69 | -5.86 | -19.61 | -13.57 | -60.38 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 11.93 | 7.32 | 5 | 1.95 | 11 | |||||
SG&A Margin | 23.84 | 38.64 | 32.59 | 29.2 | 34.77 | |||||
EBITDA Margin % | -8.23 | -44.28 | -32.73 | -15.98 | -23.76 | |||||
EBITA Margin % | -16.01 | -50.61 | -39.97 | -20.35 | -28.07 | |||||
EBIT Margin % | -16.2 | -50.62 | -40.1 | -20.66 | -29.06 | |||||
Income From Continuing Operations Margin % | -29.59 | -36.83 | -101.44 | -49.36 | -153.24 | |||||
Net Income Margin % | -30.47 | -36.83 | -101.44 | -49.36 | -153.24 | |||||
Net Avail. For Common Margin % | -28.12 | -36.83 | -101.44 | -49.36 | -153.24 | |||||
Normalized Net Income Margin | -10.85 | -29.69 | -54.4 | -50.67 | -87.34 | |||||
Levered Free Cash Flow Margin | -38.64 | -30.38 | -26.41 | -60.85 | -22.38 | |||||
Unlevered Free Cash Flow Margin | -25.62 | -17.41 | -20.65 | -56.72 | -19.7 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.2 | 0.14 | 0.17 | 0.22 | 0.3 | |||||
Fixed Assets Turnover | 1.03 | 0.94 | 1.11 | 1.43 | 1.45 | |||||
Receivables Turnover (Average Receivables) | 9.59 | 7.36 | 7.03 | 4.49 | 4.61 | |||||
Inventory Turnover (Average Inventory) | 2.08 | 1.21 | 1.38 | 2.07 | 2.1 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.75 | 2.86 | 2.5 | 2.33 | 3.22 | |||||
Quick Ratio | 1.97 | 1.59 | 1.39 | 1.55 | 1.12 | |||||
Operating Cash Flow to Current Liabilities | -0.07 | -0.78 | -0.27 | -0.27 | -0.8 | |||||
Days Sales Outstanding (Average Receivables) | 38.07 | 49.58 | 51.92 | 81.43 | 79.17 | |||||
Days Outstanding Inventory (Average Inventory) | 175.36 | 301 | 265.29 | 176.63 | 174.05 | |||||
Average Days Payable Outstanding | 29.76 | 34.11 | 30.68 | 58.39 | 56.95 | |||||
Cash Conversion Cycle (Average Days) | 183.68 | 316.47 | 286.53 | 199.67 | 196.27 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 15.86 | 7.8 | 9.64 | 20.42 | 28.7 | |||||
Total Debt / Total Capital | 13.69 | 7.24 | 8.79 | 16.96 | 22.3 | |||||
LT Debt/Equity | 0.42 | 0.31 | 1.51 | 11.08 | 22.74 | |||||
Long-Term Debt / Total Capital | 0.37 | 0.29 | 1.38 | 9.2 | 17.67 | |||||
Total Liabilities / Total Assets | 18.07 | 10.5 | 13.91 | 23.54 | 27.75 | |||||
EBIT / Interest Expense | -0.78 | -2.44 | -4.35 | -3.13 | -6.78 | |||||
EBITDA / Interest Expense | -0.39 | -2.13 | -3.55 | -2.42 | -5.54 | |||||
(EBITDA - Capex) / Interest Expense | -0.47 | -2.16 | -4.04 | -10.61 | -6.94 | |||||
Total Debt / EBITDA | -8.05 | -1.12 | -1.42 | -4.36 | -2.04 | |||||
Net Debt / EBITDA | 12.03 | 1.11 | 0.97 | -0.08 | -1.37 | |||||
Total Debt / (EBITDA - Capex) | -6.71 | -1.1 | -1.25 | -0.99 | -1.63 | |||||
Net Debt / (EBITDA - Capex) | 10.02 | 1.1 | 0.85 | -0.02 | -1.1 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -8.05 | -32.82 | 14.76 | 24.78 | 0.82 | |||||
Gross Profit, 1 Yr. Growth % | -29.88 | -58.77 | -21.66 | -51.42 | 469.66 | |||||
EBITDA, 1 Yr. Growth % | -150.56 | 261.55 | -15.18 | -39.09 | 49.9 | |||||
EBITA, 1 Yr. Growth % | 512.98 | 112.34 | -9.38 | -36.46 | 39.06 | |||||
EBIT, 1 Yr. Growth % | 181.99 | 109.89 | -9.09 | -35.7 | 41.8 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -78.24 | -16.38 | 216.06 | -39.28 | 213 | |||||
Net Income, 1 Yr. Growth % | -82.99 | -18.8 | 216.06 | -39.28 | 213 | |||||
Normalized Net Income, 1 Yr. Growth % | -84.14 | 83.81 | 110.23 | 16.22 | 73.79 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -82.09 | -24.91 | 204.71 | -38.09 | 213.01 | |||||
Accounts Receivable, 1 Yr. Growth % | -31.91 | 15.98 | 23.82 | 152.78 | -62.83 | |||||
Inventory, 1 Yr. Growth % | 19.94 | 22.52 | -11.7 | -17.64 | 0.21 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -38.89 | -4.43 | -2.25 | -4.45 | 4.61 | |||||
Total Assets, 1 Yr. Growth % | 1.12 | -6.69 | -9.28 | -0.6 | -47.07 | |||||
Tangible Book Value, 1 Yr. Growth % | -3.38 | 2.9 | -19.56 | -17.75 | -54.09 | |||||
Common Equity, 1 Yr. Growth % | -1.12 | 1.93 | -12.74 | -11.71 | -49.98 | |||||
Cash From Operations, 1 Yr. Growth % | -180.41 | 461.31 | -60.98 | 18.29 | 16.24 | |||||
Capital Expenditures, 1 Yr. Growth % | 100.24 | -75.61 | 768.43 | 1.39K | -88.81 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -174.26 | -47.18 | -0.24 | 187.45 | -62.92 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -141.71 | -54.35 | 36.12 | 242.78 | -64.99 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 1.53 | -21.41 | -12.2 | 19.66 | 12.16 | |||||
Gross Profit, 2 Yr. CAGR % | -44.34 | -46.23 | -43.17 | -38.31 | 66.35 | |||||
EBITDA, 2 Yr. CAGR % | -67.53 | 35.2 | 75.12 | -28.12 | -4.44 | |||||
EBITA, 2 Yr. CAGR % | -56.68 | 260.77 | 38.72 | -24.12 | -6 | |||||
EBIT, 2 Yr. CAGR % | -57.94 | 143.28 | 38.13 | -23.54 | -4.51 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -46.87 | -57.34 | 62.57 | 38.53 | 37.85 | |||||
Net Income, 2 Yr. CAGR % | -48.53 | -62.84 | 60.2 | 38.53 | 37.85 | |||||
Normalized Net Income, 2 Yr. CAGR % | -58.54 | -46 | 96.58 | 56.32 | 42.12 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -60.02 | -63.33 | 51.27 | 37.35 | -56.9 | |||||
Accounts Receivable, 2 Yr. CAGR % | -18.28 | -11.14 | 19.83 | 76.92 | -3.06 | |||||
Inventory, 2 Yr. CAGR % | -5.16 | 21.23 | 4.01 | -14.72 | -9.15 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -30.29 | -23.58 | -3.35 | -3.36 | -0.02 | |||||
Total Assets, 2 Yr. CAGR % | -9.03 | -2.87 | -8 | -5.04 | -27.46 | |||||
Tangible Book Value, 2 Yr. CAGR % | 12.76 | -0.29 | -9.02 | -18.66 | -38.55 | |||||
Common Equity, 2 Yr. CAGR % | 8.22 | 0.39 | -5.69 | -12.23 | -33.55 | |||||
Cash From Operations, 2 Yr. CAGR % | -8.86 | 112.45 | 47.99 | -32.06 | 17.26 | |||||
Capital Expenditures, 2 Yr. CAGR % | -55.89 | -30.12 | 45.53 | 1.04K | 29.13 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 3.46 | -37.37 | -27.41 | 69.34 | 3.24 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 25.97 | -56.37 | -21.17 | 116.01 | 9.55 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | -17.61 | -11.53 | -10.84 | -1.28 | 13.02 | |||||
Gross Profit, 3 Yr. CAGR % | -23.75 | -49.64 | -39.05 | -46.06 | 29.43 | |||||
EBITDA, 3 Yr. CAGR % | 13.41 | -27.49 | 15.74 | 23.16 | -8.16 | |||||
EBITA, 3 Yr. CAGR % | 35.46 | -26.42 | 127.63 | 6.93 | -7.14 | |||||
EBIT, 3 Yr. CAGR % | 8.77 | -28.13 | 75.23 | 7.05 | -6.06 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -0.57 | -38.19 | -16.84 | 17.08 | 81.78 | |||||
Net Income, 3 Yr. CAGR % | -3.2 | -40.09 | -24.14 | 15.93 | 81.78 | |||||
Normalized Net Income, 3 Yr. CAGR % | -4.67 | -31.89 | -15.05 | 64.99 | 61.93 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -30.03 | -50.67 | -25.72 | 12.31 | -17.28 | |||||
Accounts Receivable, 3 Yr. CAGR % | -37.92 | -8.16 | -0.75 | 53.69 | 5.18 | |||||
Inventory, 3 Yr. CAGR % | -15.51 | 3.29 | 9.07 | -3.77 | -10.01 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | -23.15 | -22.56 | -17.04 | -3.72 | -0.77 | |||||
Total Assets, 3 Yr. CAGR % | -1.65 | -8.26 | -5.05 | -5.59 | -21.85 | |||||
Tangible Book Value, 3 Yr. CAGR % | 16.45 | 9.37 | -7.18 | -12.03 | -32.78 | |||||
Common Equity, 3 Yr. CAGR % | 8.77 | 6.08 | -4.19 | -7.74 | -27.23 | |||||
Cash From Operations, 3 Yr. CAGR % | -3.44 | 67.06 | 20.76 | 37.35 | -18.74 | |||||
Capital Expenditures, 3 Yr. CAGR % | -25.37 | -63.79 | 61.87 | 215.99 | 143.75 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 160.55 | -17.31 | -26.85 | 14.85 | 2.07 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 84.1 | -10.19 | -36.24 | 28.66 | 17.78 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | -7.85 | -13.61 | -15.49 | -0.17 | -2.26 | |||||
Gross Profit, 5 Yr. CAGR % | -22.23 | -4.41 | -32.21 | -45.38 | -8.92 | |||||
EBITDA, 5 Yr. CAGR % | -0.85 | 1.29 | 34.94 | -27.74 | 7.2 | |||||
EBITA, 5 Yr. CAGR % | 36.25 | -2.03 | 36.75 | -25.51 | 59.8 | |||||
EBIT, 5 Yr. CAGR % | 38.42 | -2.21 | 19.68 | -26.33 | 37.45 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 124.4 | -6.71 | 21.04 | -14.64 | 1.8 | |||||
Net Income, 5 Yr. CAGR % | 256.85 | -6.87 | 18.41 | -16.22 | -3.67 | |||||
Normalized Net Income, 5 Yr. CAGR % | 32.57 | -8.58 | 27.34 | -5.05 | 4.37 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 178.81 | -28.07 | -4.76 | -25.7 | -40.25 | |||||
Accounts Receivable, 5 Yr. CAGR % | -28.88 | -28.25 | -19.24 | 19.38 | -1.68 | |||||
Inventory, 5 Yr. CAGR % | -10.69 | -7.21 | -8.19 | -4.33 | 1.38 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | -4.8 | -17.14 | -15.77 | -15.38 | -10.61 | |||||
Total Assets, 5 Yr. CAGR % | 0.18 | -1.84 | -4.24 | -6.98 | -14.75 | |||||
Tangible Book Value, 5 Yr. CAGR % | 4.2 | 9.24 | 5.5 | -2.84 | -21.29 | |||||
Common Equity, 5 Yr. CAGR % | 4.64 | 7.5 | 2.74 | -1.66 | -17.23 | |||||
Cash From Operations, 5 Yr. CAGR % | -26.71 | -18.29 | 14.54 | 16.57 | 19.35 | |||||
Capital Expenditures, 5 Yr. CAGR % | -19.98 | -44.6 | -2.52 | 43.76 | 47.88 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 45.22 | -11.03 | 56.28 | 10.15 | -16.04 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 44.22 | -17.71 | 31.13 | 27.58 | -20.83 |
- Stock Market
- Equities
- A195990 Stock
- Financials Abpro Bio Co., Ltd.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















